Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

The S&P 500 gave up 0.2%, with Pfizer off more than 3%. The tech-heavy Nasdaq composite edged into positive ground with a 0.2% gain on Tuesday. The tech-dominated index broke a three-day losing streak ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Trading at a bit under $25 apiece, Pfizer 's (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above ...